NeOnc Strengthens Financial Leadership with New Chief Accounting Officer

Event summary

  • NeOnc Technologies Holdings, Inc. appointed David Choi as Chief Accounting Officer on March 13, 2026.
  • Choi brings over a decade of experience in accounting, financial reporting, and internal controls for public and private companies.
  • Prior to NeOnc, Choi was a Director at Blythe Global Advisors, advising on technical accounting, SEC reporting, and SOX compliance.
  • NeOnc's NEO100™ and NEO212™ therapeutics are in Phase II clinical trials under FDA Fast-Track and IND status.

The big picture

NeOnc’s appointment of David Choi as Chief Accounting Officer underscores the company’s focus on strengthening financial governance amid its clinical-stage advancements. As a multi-Phase 2 biopharmaceutical company, NeOnc is navigating the complex regulatory and financial landscape of CNS cancer therapies, where robust internal controls are critical for scaling operations and securing investor confidence. The move aligns with broader industry trends where biotech firms prioritize financial infrastructure to support clinical and commercial milestones.

What we're watching

Financial Governance
How Choi’s expertise will impact NeOnc’s financial reporting and internal controls as it advances clinical trials.
Clinical Progress
The pace at which NeOnc’s Phase II trials for NEO100 and NEO212 will yield results under FDA Fast-Track status.
Strategic Expansion
Whether NeOnc can sustain its global operations and corporate growth while maintaining rigorous financial controls.

Related topics

Clinical Trials